Wnt/beta-catenin modulation: A promising frontier in chronic kidney disease management

Shubhangi Saxena1, Neha Dagar1, Vishwadeep Shelke1

  • 1Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Pilani Campus, Pilani, Rajasthan, India.

Abstract

Insights

Targeting the Wnt/β-catenin pathway shows promise for managing chronic kidney disease (CKD). Modulating this conserved signaling pathway offers effective therapeutic strategies for alleviating CKD progression.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) affects 850 million globally, posing significant health challenges.
  • The Wnt/β-catenin signaling pathway is crucial for kidney homeostasis and is dysregulated in CKD.
  • β-catenin expression increases in adult kidneys under stress, making it a potential therapeutic target.

Purpose of the Study:

  • To review the significance of targeting the Wnt/β-catenin signaling pathway for CKD management.
  • To highlight the role of Wnt/β-catenin modulation in alleviating CKD.

Main Methods:

  • Comprehensive literature review using PubMed, Scopus, Science Direct, and Google Scholar.
  • Focused on studies investigating Wnt/β-catenin signaling in CKD and related therapeutic interventions.

Main Results:

  • Summarizes pharmacological therapies that modulate the Wnt/β-catenin axis in CKD.
  • Highlights promising preclinical findings that support future clinical investigations.

Conclusions:

  • Wnt/β-catenin signaling is a highly conserved pathway critical to CKD progression.
  • Therapies targeting Wnt/β-catenin signaling represent effective strategies for CKD treatment.

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.7K
Nephrons01:10

Nephrons

The kidneys are intricate organs with millions of working units known as nephrons. Each nephron features two major structures: the renal corpuscle, which facilitates blood plasma filtration, and the renal tubule, which handles the glomerular filtrate. Blood supply is directly linked to the nephrons. The renal corpuscle consists of the glomerulus, a capillary network, and the Bowman's capsule, a double-walled epithelial structure that encases the glomerulus. The filtering of blood plasma...
2.3K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K
Renal Tubule and Collecting Duct01:24

Renal Tubule and Collecting Duct

The renal tubule is divided into three parts: the proximal convoluted tubule (PCT), the Loop of Henle (LOH), and the distal convoluted tubule (DCT).
Proximal Convoluted Tubule (PCT):
The PCT is the initial segment of the renal tubule, extending from the Bowman's capsule that encloses the glomerulus. Its convoluted structure and microvilli-lined cells increase the surface area for reabsorption. The PCT reabsorbs glucose, amino acids, sodium, and water from the filtrate, ensuring essential...
880
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406